Summary & Overview
HCPCS J9325: Talimogene Laherparepvec Injection, per 1M PFU
HCPCS Level II code J9325 identifies the per-unit billing for talimogene laherparepvec, an intralesional oncolytic immunotherapy dosed per 1 million plaque forming units. This code matters nationally as use of oncolytic viral therapies expands for certain cutaneous, subcutaneous, and nodal malignancies, affecting oncology drug spend, site-of-care payment differentials, and coverage policy development.
Key national payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9325 represents clinically, typical sites of service, and the billing context for per-unit drug reporting. The publication summarizes available benchmarks and reimbursement considerations, highlights payer coverage themes and common modifier usage, and provides clinical context for intralesional administration of talimogene laherparepvec.
The piece is designed to inform billing managers, oncology practice administrators, and policy analysts about code definition, where services are delivered, and the elements that influence billing and coverage for this injectable biologic. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9325 represents injection, talimogene laherparepvec, per 1 million plaque forming units. This code denotes administration of an oncolytic viral therapy designed for intralesional injection directly into cutaneous, subcutaneous, or nodal lesions. The service type is intralesional injectable immunotherapy, and the typical site of service is outpatient oncology clinics, physician offices, or hospital outpatient departments where oncology procedures and injections are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with injectable, unresectable cutaneous, subcutaneous, or nodal melanoma lesions appropriate for intralesional oncolytic viral therapy. The patient presents to an outpatient oncology infusion suite or dermatology procedural clinic for administration of J9325 (injection, talimogene laherparepvec, per 1 million plaque forming units). Prior to the visit, staging and pathology confirm melanoma suitable for intralesional therapy and baseline tumor measurements are documented. On the day of service, the patient is evaluated by the treating physician or advanced practice provider; informed consent and a focused exam of the target lesions are performed. Lesions are cleansed and prepared; local anesthesia may be used. Talimogene laherparepvec is supplied in vials quantified by plaque forming units; the required dose is calculated by multiplying the number of millions of plaque forming units needed and billing J9325 units accordingly. The medication is injected directly into the tumor(s) using sterile technique. Typical site of service is an outpatient infusion center, physician office-based procedure room, or ambulatory surgery center when multiple lesions or deeper injections require monitored sedation. Post-injection monitoring for adverse events (flu-like symptoms, local necrosis, injection-site reaction, herpes-related complications) occurs for a brief observation period. Documentation includes lesion sites, volumes administered, lot numbers, patient tolerance, and any immediate complications. Subsequent treatment visits follow protocol intervals with tumor response assessments and imaging as indicated. Payors involved may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage and billing adjudication.
Coding Specifications
| Modifier | Description |
|---|